Spero Therapeutics (STU:2HA) Earnings per Share (Diluted) : €0.39 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics Earnings per Share (Diluted)?

Spero Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was €0.89. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.39.

Spero Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was €0.89. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.39.

Spero Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was €0.89. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €0.46.

During the past 9 years, Spero Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 42.40% per year. The lowest was -18.50% per year. And the median was 5.20% per year.

Spero Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Spero Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Earnings per Share (Diluted) Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-3.02

-2.89

-2.58

-1.16

0.39

Spero Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.52	-0.23	-0.21	-0.06	0.89

Competitive Comparison of Spero Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Spero Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's PE Ratio falls into.

Spero Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Spero Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(20.913	-	0)	/	52.989
	=	0.39

Spero Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(46.942	-	0)	/	54.145
	=	0.87

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.39

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Spero Therapeutics (STU:2HA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Spero Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines